Brineura, an enzyme replacement, is the first and only product to treat CLN2 disease.
Brineura is administered to the cerebrospinal fluid via intraventricular infusion.
Stay current on the latest news about CLN2 disease and Brineura by signing up to receive email updates from BioMarin.
Brineura is contraindicated in patients with:
Brineura has not been studied in pregnancy or lactation.
Safety and effectiveness in pediatric patients below 3 years of age have not been established.